The aim of this systematic review and meta-analysis is to evaluate the pros and cons of adjuvant low dose intrathecal meperidine for spinal anaesthesia. We searched electronic databases for randomized controlled trials using trial sequential analysis (TSA) to evaluate the incidence of reduced rescue analgesics, shivering, pruritus, nausea and vomiting when applying adjuvant intrathecal meperidine. Twenty-eight trials with 2216 patients were included. Adjuvant intrathecal meperidine, 0.05-0.5 mg kg Occurring in about half of patients receving spinal anaesthesia, shivering 1 is an undesirable outcome for surgical patients linked to impaired thermoregulatory control 2-4 . Shivering generates heat to maintain body temperature, but it induces stress responses, interferes with surgical procedure and anaesthesia monitoring, and causes postoperative pain and discomfort [5] [6] [7] [8] . In addition, perioperative shivering causes lactic acidosis, increases blood, intraocular and intracranial pressure as well as metabolic demand and oxygen consumption 5, [9] [10] [11] [12] . Meperidine is an intermediate lipid soluble opioid with potent local anaesthetic properties [13] [14] [15] . With dosage of 0.5-1.0 mg kg −1 intrathecally for spinal anaesthesia, meperidine provided adequate sensory blockage and postoperative analgesia [15] [16] [17] [18] . However, drowsiness and pruritus might occur along with nausea, vomiting and even respiratory depression at such a high dose intrathecal meperidine [19] [20] [21] [22] . Due to the above adverse effects, combining local anaesthetics with relatively lower dosage, 0.05-0.5 mg kg −1 intrathecal meperidine, were suggested to provide adequate analgesia with less side effects [21] [22] [23] [24] . Although intrathecal meperidine was suggested for both analgesia and shivering prevention in spinal anaesthesia, comprehensive evidence for and against this is lacking 1 . Controversies exist about the dose-dependent
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Data extraction. Two reviewers (Y.C.L. and C.Y.C.) extracted the baseline as well as all outcome data, includ-
ing the study design, the participant data, the inclusion and exclusion criteria, the type of surgery, temperature control, spinal anaesthetic techniques and drugs adopted, and any resulting complications. If an agreement could not be reached, the dispute was resolved with the help of a third reviewer (C.C.C.). To overcome unit-of-analysis error, we combined groups to create a single pair-wise comparison for the final analysis, and divided the "shared" group equally in subgroup analyses in comparing different regimen of low dose groups, as the Cochrane handbook recommended 35 .
Methodological quality appraisal.
We assessed the quality of each study based on the adequacy of randomization, the allocation concealment, the blinding of the patients and the outcome assessors, the length of the follow-up period, the reporting of study withdrawals, the performance of an intention-to-treat analysis, and other potential bias assessed by Cochrane Collaboration's tool 36 . Disagreements about subtracted data were adjudicated by a third reviewer (C.C.C.).
Outcomes and Statistical Analysis. The primary outcome was the incidence and intensity of shivering after receiving spinal anaesthesia. The secondary outcomes included the need for rescue analgesics during the surgery, and related complications such as nausea, vomiting, pruritus, hypotension and bradycardia. We conducted meta-analysis with the Review Manager, version 5.3 (Cochrane Collaboration, Oxford, England), applying trial sequential analysis (TSA) software version 0.9.5.5 beta (http://www.ctu.dk/tsa/) 37 , SAS 9.4 (SAS Institute Inc., Cary, NC, USA) software for meta-regression, and Comprehensive Meta Analysis Version 2 (NJ, USA) for publication bias. A random-effects model was used to calculate the pooled estimates of adjusted relative risk (RR). Standard deviations were estimated from the confidence interval (CI) limit, and the standard error or range values were provided from studies cited. The effect sizes of dichotomous outcomes were reported as RR and the precision value based on a 95% CI. A pooled estimate of value was calculated using the DerSimonian and Laird random-effects model 38 .
To evaluate the statistical heterogeneity and the inconsistency of treatment effects across the studies, the Cochrane Q test and I 2 statistics were used, respectively. Statistical significance was set at 0.10 for the Cochrane Q test. The Egger test was used to assess the funnel plot for significant asymmetry, indicating possible publication or other bias 39 . The "trim and fill" method was used to test and adjust publication bias 40, 41 .
Trial sequential analysis (TSA). TSA combines information size estimation for meta-analysis (cumulated sample size of included trials) with an adjusted threshold for statistical significance in the cumulative meta-analysis which called trial sequential monitoring boundaries 37 . Trial sequential analysis could help us reduce the risk of random error, to increase the robustness of the meta-analyses, and to determine whether the current sample size is sufficiently enough. We applied TSA to the cumulative meta-analysis for all outcomes during spinal anaesthesia 37 . TSA is conducted with an overall 5% of a type I error and a power of 80%. We calculated the alpha-spending adjusted required sample size based on the relative risk reduction (RRR) of each outcome. The cumulative z-curve was constructed using a random-effects model. We set the 95% confidence intervals adjusted for scattered data and repetitive testing. 
Meta-regression.
We conducted meta-regression to assess the relationship between one or more covariates (moderators) and primary outcome. In this study, potential covariates such as age, meperidine dose, and sample size of each study will be evaluated to determine whether they are the source of heterogeneity.
Sensitivity analyses.
We conducted sensitivity analyses to evaluate methodological quality, participants and spinal anaesthesia techniques to test the stability of the integration effect and to assess statistical heterogeneity. Regarding the quality assessment, bias of selection, performance, detection and attrition were excluded. If random sequence generation and allocation concealment were both unclearly reported or any were categorized as high-risk, we counted this as selection bias.
Results
Trial characteristics. Among 2373 initially evaluated abstracts, 227 studies met the initial inclusion criteria (Fig. 1) , 199 trials were subsequently excluded, one study did not use spinal anaesthesia, one did not use the same local anaesthetics, 8 trials had different targets or non-relevant outcomes, 24 studies used intrathecal meperidine 16, 44, 47, 55 , and the other 9 focused on lower abdominal or lower limb surgery 26, 30, 33, 45, 46, [49] [50] [51] 54 . Intrathecal local anaesthetics plus meperidine group was compared with the same dose local anaesthetics alone 16, 25, 28, 42, 43, 49 or with normal saline 26, 27, [29] [30] [31] [32] [44] [45] [46] [47] [48] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] or with 10% glucose water 33 as controls. Five studies evaluated the anti-shivering effects of intrathecal fentanyl with meperidine 46, 50, 53, 56, 58 , three trials interrogated it with intrathecal morphine 28, 43, 54 and one with intravenous ondansetron 30 . Two trials added morphine for both the experimented and the controlled 52, 57 , while one contained epinephrine 58 . Eight studies investigated various doses of intrathecal meperidine 16, [25] [26] [27] 42, 43, 53, 59 . In terms of the intrathecal local anaesthetic drug, bupivacaine was used in 21 studies [25] [26] [27] [28] [30] [31] [32] [42] [43] [44] [45] [46] 48, [50] [51] [52] [53] [54] 56, 57, 59 , lidocaine in 5 trials 16, 29, 47, 55, 58 , and tetracaine in 2 RCTs 33, 49 . Intravenous sedation was combined with spinal anaesthesia in 4 studies 16, 49, 51, 54 , and prehydration was neither given nor disclosed in 4 trials 16, 45, 51, 54 . Ten RCTs did not provide information on hypothermia prevention [31] [32] [33] 45, 47, 50, [52] [53] [54] 58 . Patient characteristics, spinal anaesthesia techniques and surgical procedures are summarized in Table 1 .
The quality assessment of RCT methodology is shown in Supplementary Table 1 . Acceptable sequence generation was noted in 18 studies 16, [25] [26] [27] [28] [30] [31] [32] [42] [43] [44] [46] [47] [48] 52, 55, 57, 59 , while one had poor quality 29 and the rest were unclear. How allocation concealment was carried out was clearly described in 11 RCTs 26, [28] [29] [30] [31] [32] 47, 48, 52, 57, 59 . Performance bias was found in 5 studies 30, 33, 50, 51, 54 , while detection bias was identified in 13 trials 32, 33, [42] [43] [44] [49] [50] [51] [52] [53] [54] [55] 59 . Two studies performed a per-protocol analysis, and 7 patients were withdrawn in total during the follow-up periods 28, 45 . Other biases included differences in shivering assessment scales 46, 49 , existence of data error 26, 47, 59 , combination with epidural anaesthesia 28, 42, 43 , and nondisclosure of intraoperative shivering data 31 and spinal needle size 28, 42, 43 .
Main outcomes with TSA. Trial sequential analysis provides the necessary sample size for our meta-analysis and boundaries that determine whether the evidence in our meta-analysis is reliable and conclusive. The overall incidence of shivering derived from 21 RCTs [25] [26] [27] [28] [29] [30] [31] [32] [42] [43] [44] [45] [46] [47] [48] [49] 51, [55] [56] [57] 59 (n = 1535) was significantly reduced in the adjuvant low dose meperidine groups when compared with control, with an RR of 0.31 (95% CI, 0.24 to 0.40, P < 0.00001; I 2 = 42%) (Fig. 2) , relative risk reduction (RRR) of 66.1%, absolute risk reduction (ARR) of 29.2%, and numbers needed to treat (NNTs) 3.4.
If the cumulative z-curve crosses the trial sequential monitoring boundary, a sufficient level of evidence has been reached and no further trials are needed. If the z-curve does not cross the boundary and the required information size has not been reached there is insufficient evidence to reach a conclusion. TSA showed the required information size of 148 patients was reached and the cumulative z-curve was touched and crossed the trial sequential monitoring boundary for benefits. The TSA adjusted RR was 0.32 (95% CI, 0.25 to 0.41; 1535 patients, 21 trials) (Fig. 3 and Table 2 ), providing firm evidence for shivering prevention. Moreover, 15 trials [25] [26] [27] [28] [29] [30] 42, 43, 46, 48, 49, 51, 56, 57, 59 (n = 1198) have further evaluated the preventive effect of adjuvant low dose intrathecal meperidine to the incidence of shivering based on a 4-level intensity scale 60 , showing that the RRs were 0.62 (95% CI, 0.41 to 0.94, P = 0.02) for grade I, 0.35 (95% CI, 0.23 to 0.53, P < 0.00001) for grade II, 0.26 (95% CI, 0.16 to 0.41, P < 0.00001) for grade III, and 0.15 (95% CI, 0.08 to 0.28, P < 0.00001) for grade IV shivering (Fig. 4) .
The need for intraoperative rescue analgesics was reduced in the adjuvant low dose meperidine groups with RR 0.27 (95% CI, 0.12 to 0.64, P = 0.003), RRR 73.3%, ARR 10.6%, and NNTs 9.5 (Fig. 4) . Our result has reached the required information size (n = 232) of TSA, and the z-curve has also crossed the conventional boundary of benefit with an adjusted RR, 0.27 (95% CI, 0.08 to 0.91; 286 patients, 4 trials) ( Table 2) . Adjuvant low dose intrathecal meperidine also increased the risk of nausea with RRs of 1.84 (95% CI, 1.29 to 2.64, P = 0.0009; I 2 = 23%; number needed to harm [NNH]: 7.8), and in vomiting with RRs of 2.23 (95% CI, 1.23 to 4.02, P = 0.008; I 2 = 19%; NNH: 9.9) (Fig. 4) . Their TSA required information size (396 and 266 patients) were both reached and their z-curve also crossed the conventional boundary of harm, with a TSA adjusted RR, 1.72 (95% CI, 1.33 to 2.23; 1247 patients, 20 trials) on nausea and 1.96 (95% CI, 1.20 to 3.21; 1108 patients, 14 trials) on vomiting, respectively ( Table 2) . These results provided a sufficient level of evidence implying that intrathecal meperidine may increase the risks of nausea and vomiting.
The RR of the incidence of pruritus when using adjuvant low dose intrathecal meperidine was 2.31 (95% CI, 0.94 to 5.70, P = 0.07; I 2 = 34%; NNH: 15.4) (Fig. 4) and the TSA required information size of 405 patients was reached. Such a conclusion was echoed by the z-curve without crossing the conventional boundary of harm (TSA adjusted RR, 1.42, 95% CI: 0.87 to 2.34; 1333 patients, 19 trials) ( Table 2 ). This result provided firm evidence showing that intrathecal meperidine may not increase bring forth the harm of pruritus. Two drug-related morbidities when using adjuvant low dose intrathecal meperidine, bradycardia and hypotension, were not increased in comparison with control groups; the RRs for these were 1.15 (95% CI, 0.54 to 2.45, P = 0.72; I 2 = 0%; NNH: 553.1) and 1.16 (95% CI, 0.97 to 1.40, P = 0.11; I 2 = 17%; NNH: 11.1), respectively. However, their TSA required information size were not reached and their z-curves did not cross the conventional boundary: TSA adjusted 95% CI cannot be calculated due to too little information on bradycardia (actual vs. required information patients size = 818/351,540 = 0.23%; 10 trials), and TSA adjusted RR, 1.15 (95% CI, 0.95 to 1.40; 1035 patients, 15 trials) on hypotension (Fig. 4 and Table 2 ). None of the boundaries for benefit or harm was crossed, showing insufficient evidence to allow us to conclude whether the intervention was harmful on the above two results.
Publication bias. The funnel plot showed the asymmetric distribution of studies and Egger's test was significant (P = 0.00018; Fig. 5a ). The "trim and fill" method results showed ten necessary studies were missed. After filling these ten with comprehensive analysis, the funnel plot showed improved symmetry (Fig. 5b) . Under the random effects model, the Mantel-Haenszel (MH) log risk ratio and 95% confidence interval for the combined studies is 0.32 (0.25 to 0.41). Imputed MH log risk ratio by "trim and fill" method is 0.41 (0.31 to 0.53). The results showed that publication bias or another confounding variable should be considered, but would not be a major influencing factor for the intervention effect. That is, the publication bias did not affect our major outcomes.
Subgroup analyses.
Subgroups of different surgical types and intrathecal meperidine doses were analysed (Table 3 ). The anti-shivering effect of intrathecal meperidine was observed in all four types of surgery, with RRs 0.30 (95% CI, 0.21 to 0.43, P < 0.00001) in caesarean section, 0.30 (95% CI, 0.14 to 0.63, P = 0.002) in lower limb Table 2 . Trial sequential analysis of incidence of outcomes under spinal anaesthesia. TSA calculated an alphaspending adjusted required information size using α = 0.05 (two-sided), β = 0.20 (power = 80%) and D2, the cumulative z-curve was constructed using a random-effects model. a
The cumulative z-score reaches significance by crossing both the conventional boundaries.
b TSA with alpha-spending adjusted confidence interval cannot be calculated, boundary required sample size is ignored due to too little information (0.23%). CI, confidence interval; D2, diversity; NA, not applicable; TSA, trial sequential analysis; RIS, required information size; RR, relative risk; z-curve, cumulative z-curve. Funnel plots was applied to assess publication bias which were plotted in the log risk ratios against their standard errors and estimating the number of missing studies that might exist in a meta-analysis and the effect that these studies might have had on its outcome. (a) Funnel plot with 95% confidence limits for testing publication bias; (b) Funnel plot of all studies with 95% CI, including hypothetical studies using 'trim and fill' method (in red) for adjusting publication bias. After adjusting for missing studies, we noted that the point estimate of the overall effect size is approximately correct and coverage of the effect size confidence intervals is substantially improved. The results showed that publication bias or another confounding variable should be considered, but would not be a major influencing factor for the intervention effect. That is, the publication bias did not affect our major outcomes.
Scientific RepoRts | 7: 15323 | DOI:10.1038/s41598-017-14917-5 orthopaedic surgery, 0.11 (95% CI, 0.03 to 0.38, P = 0.0006) in urology, and 0.42 (95% CI, 0.25 to 0.70, P = 0.0008) in other miscellaneous surgical patients, respectively. The benefit of reducing the need of rescue analgesics and the morbidities of nausea and vomiting were only noted in the subgroup of caesarean section. The subgroup analysis of intervention dose indicated that dose equal to or less than 0.2 mg kg −1 or 12.5 mg (Group I) could provide similar anti-shivering and analgesic effect (reduced need for rescue analgesics) as dose more than 0.2 mg kg (Table 3) . However, it did not decrease the occurrence of drug-related adverse events as anticipated (Supplementary Figure 1) .
Meta-regression analyses.
In the univariate meta-regression analyses, age, meperidine dose, and sample size of each study were not influenced by the heterogeneity of sources, whose coefficients were 0.002 (P = 0.94), 2.68 (P = 0.42), and 0.007 (P = 0.33), respectively (Supplementary Figure 2) . These three variables evaluated were all not significantly associated with shivering prevention. Sensitivity analyses. The sensitivity analysis of the potential bias is shown in Table 4 . After considering 13 items of potential bias in three categories, all results remained consistently significant except the incidence of nausea, which showed no statistical significance when excluding trials without using warm pre-hydration.
Subgroup

No of studies
Discussion
We demonstrated that low dose intrathecal meperidine as an adjuvant for spinal anaesthesia could effectively prevent shivering and reduce need for rescue analgesics, yet still might increase risk of nausea and vomiting. TSA further provided a sufficient level of evidence with power of accuracy and reliability for the meta-analysis 37, 61 . Previous studies noted the anti-shivering effect of intrathecal opioids 62 . Various opioids were studied by Pöpping. et al. without subgroup analysis, and meperidine was recruited in only two trials 62 . Furthermore, since the dose of local anaesthetics in experimental groups was deliberately decreased, whether the reduced risks (e.g., shivering and nausea) were related to the adjuvant opioid or reduced local anaesthetic was unclear 62 . Thus comparing meperidine as adjuvant under an equal amount of intrathecal local anaesthetics guided our meta-analysis design. Feng. et al. investigated primarily sulfentanil and showed no beneficial effect while also revealing increased the incidence of pruritus 63 . Shortcomings of that study included mixed use of spinal and epidural anaesthesia and mixed local anaesthetic drugs which have been carefully avoided in our sensitivity analyses 63 . Therefore, our results on intrathecal meperidine for the prevention on shivering under spinal anaesthesia would be more reliable due to meticulous management of this bias.
The mechanism of shivering during spinal anaesthesia is multifactorial. Sympathetic blockade caused by spinal anaesthesia impairs compensatory vasoconstriction and autonomic regulation below the level of the blockade 1, 8 , and blunts thermoregulatory processing 2,3 leading to vasodilation, heat loss and hypothermia: all these factors might contribute to shivering. Meperidine is the most common intravenousdrug used for treating and preventing shivering, as its equi-analgesic dose is much more efficient than other opioids such as fentanyl, alfentanil, sufentanil or morphine in preventing shivering 15, 64, 65 . Meperidine is the only opioid that is an agonist at both the μ and κ receptors closely related to the pathogenesis of shivering by reducing the shivering threshold and triggering decreasedcore temperature, constitutes its anti-shivering effect 15, [65] [66] [67] . Nausea and vomiting are common opioid-related side effects, but their mechanisms are extremely complex [68] [69] [70] [71] . The increased incidence of nausea and vomiting associated with intrathecal meperidine may relate to several issues. First, intrathecal meperidine could be deemed as an analgesic independently, so a higher level of anaesthesia might cause systemic hypotension, nausea and vomiting when adjuvant was given. However, none of our recruited studies had significant differences regarding anaesthetic level between the control and the meperidine group. Future studies could focus on the optimal dose of local anaesthetics and intrathecal meperidine and possible interactions. Furthermore, like morphine and other opioids, intrathecal meperidine also showed its central effect inducing nausea and vomiting 13, 32, 72 . Subgroup analyses demonstrated that the protective effect of adjuvant low dose intrathecal meperidine against shivering was demonstrated among caesarean section, urological, other lower abdominal and lower limb orthopaedic surgeries. It is particularly beneficial to elderly and obstetric patients who are vulnerable to shivering-induced oxygen consumption, metabolic demands and cardiovascular morbidities 10, [73] [74] [75] [76] . The sensitivity analyses illustrated that both therapeutic and adverse effects of intrathecal meperidine are unaffected by anaesthetic techniques, perioperative care, and patient age or physical status. The benefit of reduction of rescue analgesic in low dose intrathecal meperidine with less nausea and vomiting could not be generalized to all surgeries due to the limited RCTs included. Furthermore, reducing meperidine dosages could not prevent nausea and vomiting as anticipated. Thi. et al. showed that the dose-dependent analgesic effect of intrathecal meperidine lower than 0.5 mg kg −1 would not aggravate nausea and vomiting 24 . Although we demonstrated that dose equal to or less than 0.2 mg kg −1 or 12.5 mg could provide anti-shivering and adequate analgesia as effective as dose more than 0.2 mg kg −1 or 12.5 mg, an optimal dose of low dose intrathecal meperidine was not yet identified. Since the benefits of shivering protection and rescue analgesics reduction were not overwhelmed by nausea and vomiting, the potential utility of such interventions could be considered in clinical practice.
The are several strengths to this review. Using Cochrane methodology for a non-restricted up-to-date literature search without limitation by language or country of publication (8 countries and 5 languages) is one of our major strengths. We also attempted to correct publication bias using the'trim and fill' method 40, 41 reducing possible influence from selection reporting bias. We analysed the incidence of shivering as well as the effect on different grades of shivering, conducted sensitivity analyses to improve the reliability of our results, and performed TSA to reduce systematic and random errors and identify the threshold of statistical significance 37, 61 . TSA was applied to account for scattered data and repetitive testing on accumulated data, to calculate the required information size, and to confirm the cumulative z-curve crossing the boundary of benefit or harm in the listed outcomes 37, 61 . This meta-analysis with TSA provided us robust results and indicted that no further trials about adjuvant intrathecal meperidine on shivering prevention are needed in the current future. This is the first systematic review and meta-analysis using TSA to validate the benefits and harms of intrathecal meperidine for patients undergoing spinal anaesthesia.
Our study has several limitations. First, although various biases among all RCTs included have been considered under sensitivity analysis and three possible covariables were also assessed by meta-regression, results remained moderately heterogenious and other covaribles were unidentified. This implies that the conclusion needs to be carefully intepreted and applied in clinical practice due to the existence of qualitative and statistical heterogeneity for our overall incidence of shivering as well as specific findings such as pruritus, nausea and vomiting. Second, as this study specified single medication through single route,the dose-response effect of adjuvant intrathecal meperidine with local anaesthetics remains unclear and needs further investigation using network meta-analysis [77] [78] [79] . Third, local anaesthetics per se used in spinal anaesthesia could induce sympathetic blockade, hypotension and nausea/vomiting, which might interfere with observations regarding side effects induced by intrathecal meperidine. Fourth, although subgroup analysis for types of surgeries has been considered, caesearean section surgeries contributed the majority of the database. The application of the study outcome to other surgeries needs to be further evaluated.
Conclusion
Our meta-analysis with TSA validates the effectiveness of shivering prevention by adjuvant low dose intrathecal meperidine with local anaesthetics for spinal anaesthesia with reduced intraoperative need for rescue analgesics, but it also noted increased incidence of nausea and vomiting. Further larger RCTs or network meta-analyses are needed to evaluate different doses of intrathecal meperidine as well as other routes of administration to help anaesthesiologists provide better care in clinical practice.
